About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC
By
John Conibear
2 Videos
0 views
March 8, 2023
Comments
0
Login to view comments.
Click here to Login
Featured Video
08:44
Johnson & Johnson
Management and Proactive Care of Adverse Events Associated with Loca…
Feat.
J. Sabari,
A. Spira
Featured Video
06:27
Johnson & Johnson
Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC
Feat.
M. Socinski,
D. Waterhouse
Recommended
AUTOPLAY
ON
Related
Newest
17:20
Total Health
2024 Intervention Selection & Sequencing in Early Stage NSCLC
Feat.
J. Porter
18:47
Total Health
Updates in the Management of NSCLC: Systemic Therapy Year in Review
Feat.
W. Iams
11:07
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…
Feat.
J. West
36:14
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …
Feat.
B. Halmos
29:25
Young Chae
Hyperprogression in Cancer Treated With Immunotherapy
17:34
ecancer
Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…
Feat.
L. Raez
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage
Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …
Feat.
E. Rodriguez
19:33
ecancer
ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC
Feat.
E. Felip,
A. Spira,
A. Passaro,
A. Addeo
09:37
Luis Raez
Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…
07:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…
Feat.
J. West
20:27
Yale Cancer Center
Progress in the Treatment of NSCLC
Feat.
R. Herbst
22:27
2024 ASCO® Annual Meeting Insights Hub
Developmental Therapeutics Highlights From ASCO® 2024
Feat.
G. Sonpavde
26:42
Total Health
ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…
Feat.
J. Bauman
23:36
CHEST 2022 Coverage
Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer
Feat.
J. Possick
17:57
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Expert Discussion on New Treatment Options…
Feat.
D. Carbone,
B. Stiles
08:15
ecancer
ESMO 2023 Summary: "Highlights From Recent NSCLC Trials"
Feat.
B. Gyawali
20:43
GRACE
Newer Types of Treatment for Lung Cancer: ADCs and Bispecifics
Feat.
L. Bazhenova
23:29
2023 Evolution Conference
IO and Targeted Treatment for mNSCLC
Feat.
M. Mooradian
03:44
ecancer
ASCO® 2023 Insights: "Dr. Wakelee on KEYNOTE-671 Study Updates …
Feat.
H. Wakelee
07:38
GRACE
How Does PD-L1 Score Affect Treatment Options for NSCLC
Feat.
S. Patel,
T. Leal,
P. Iyengar,
A. Desai,
C. Kim,
J. Rotow
